Literature DB >> 8624817

Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity.

M Kamanaka1, P Yu, T Yasui, K Yoshida, T Kawabe, T Horii, T Kishimoto, H Kikutani.   

Abstract

CD40-deficient mice are susceptible to Leishmania major infection while their wild-type littermates can resolve the infection. Upon stimulation with L. major antigens, draining lymph node T cells of the mutant mice and the susceptible mice, BALB/c, secrete comparable amounts of IL-4. The mutant mice produce less IFN gamma than wild-type mice. The expression of IL-12 p40 mRNA was significantly lower in L. major antigen-stimulated cells of mutant mice than those of wild-type or BALB/c mice. In normal mice, engagement of CD40 activates macrophages to a leishmanicidal state in vitro in the presence of IFN gamma. The results suggest that the CD40-CD40 ligand interaction plays an important role in two critical steps of cell-mediated immunity to L. major infection: the generation of a Th1 response and activation of macrophages to a leishmanicidal state.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8624817     DOI: 10.1016/s1074-7613(00)80435-5

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  76 in total

1.  Absence of CD40-CD40 ligand interactions in X-linked hyper-IgM syndrome does not affect differentiation of T helper cell subsets.

Authors:  H Uronen; R E Callard
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Associations between autoimmune thyroid disease prognosis and functional polymorphisms of susceptibility genes, CTLA4, PTPN22, CD40, FCRL3, and ZFAT, previously revealed in genome-wide association studies.

Authors:  Naoya Inoue; Mikio Watanabe; Hiroya Yamada; Kazuya Takemura; Fumiaki Hayashi; Noriko Yamakawa; Maiko Akahane; Yu Shimizuishi; Yoh Hidaka; Yoshinori Iwatani
Journal:  J Clin Immunol       Date:  2012-06-17       Impact factor: 8.317

3.  Acquired, but not innate, immune responses to Streptococcus pneumoniae are compromised by neutralization of CD40L.

Authors:  Y i Hwang; M H Nahm; D E Briles; D Thomas; J M Purkerson
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

4.  CD40 induces macrophage anti-Toxoplasma gondii activity by triggering autophagy-dependent fusion of pathogen-containing vacuoles and lysosomes.

Authors:  Rosa M Andrade; Matthew Wessendarp; Marc-Jan Gubbels; Boris Striepen; Carlos S Subauste
Journal:  J Clin Invest       Date:  2006-09       Impact factor: 14.808

5.  Nitric oxide contributes to host resistance against experimental Taenia crassiceps cysticercosis.

Authors:  Javier Alonso-Trujillo; Irma Rivera-Montoya; Miriam Rodríguez-Sosa; Luis I Terrazas
Journal:  Parasitol Res       Date:  2007-01-06       Impact factor: 2.289

Review 6.  Sex hormones and modulation of immunity against leishmaniasis.

Authors:  Heidi Snider; Claudio Lezama-Davila; James Alexander; Abhay R Satoskar
Journal:  Neuroimmunomodulation       Date:  2009-02-11       Impact factor: 2.492

Review 7.  CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes.

Authors:  A Bhushan; L R Covey
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

8.  CD40 is required for protective immunity against liver stage Plasmodium infection.

Authors:  Sara A Murray; Isaac Mohar; Jessica L Miller; Katherine J Brempelis; Ashley M Vaughan; Stefan H I Kappe; Ian N Crispe
Journal:  J Immunol       Date:  2015-02-02       Impact factor: 5.422

Review 9.  The CD40 ligand. At the center of the immune universe?

Authors:  I S Grewal; R A Flavell
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

10.  A Salmonella typhi OmpC fusion protein expressing the CD154 Trp140-Ser149 amino acid strand binds CD40 and activates a lymphoma B-cell line.

Authors:  Mario I Vega; Leopoldo Santos-Argumedo; Sara Huerta-Yepez; Rosendo Luría-Perez; Vianney Ortiz-Navarrete; Armado Isibasi; Cesar R González-Bonilla
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.